刘人杰

    【摘要】 目的：探討重组人血管内皮抑制素(rh-Endo)联合SP方案治疗晚期胃癌的效果及对患者血清CA199、CA724和CEA水平的影响。方法：选取2019年2月-2020年2月本院收治的86例晚期胃癌患者，采用随机数字表法分为对照组与观察组，每组43例。对照组给予SP方案治疗，观察组在对照组加用rh-Endo治疗，比较两组近期疗效，不良反应，血清CA199、CA724和CEA水平及复发转移与生存情况。结果：观察组ORR(53.49%)、DCR(79.07%)分别高于对照组的ORR(30.23%)、DCR(58.14%)(P<0.05);两组口腔黏膜炎、乏力、消化道反应、白细胞减少、神经毒性、心电图异常、肝肾功能异常等发生率比较，差异均无统计学意义(P>0.05);治疗后，观察组血清CA199、CA724和CEA水平均低于对照组(P<0.05);观察组随访12～24个月复发或远处转移率低于对照组，无病生存率、总生存率均高于对照组(P<0.05)。结论：rh-Endo联合SP方案治疗晚期胃癌的近远期效果确切，可降低血清CA199、CA724和CEA水平，减少肿瘤负荷，延长生存期。

    【关键词】 重组人血管内皮抑制素 SP方案 胃癌 晚期 CA199 CA724 CEA

    [Abstract] Objective： To investigate the effect of Recombinant Human Endostatin (rh-Endo) combined with SP regimen in the treatment of advanced gastric cancer and its effect on the serum CA199， CA724 and CEA levels of patients. Method： A total of 86 patients with advanced gastric cancer admitted to our hospital from February 2019 to February 2020 were selected and divided into two groups by random number table ......